- Home
- NPCE vs TNXP Comparison
NPCE vs TNXP Comparison
Compare NPCE & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- TNXP
- Stock Information
- Founded
- NPCE 1997
- TNXP 2007
- Country
- NPCE United States
- TNXP United States
- Employees
- NPCE N/A
- TNXP N/A
- Industry
- NPCE Medical Specialities
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- TNXP Health Care
- Exchange
- NPCE Nasdaq
- TNXP Nasdaq
- Market Cap
- NPCE 292.9M
- TNXP 335.6M
- IPO Year
- NPCE 2021
- TNXP N/A
- Fundamental
- Price
- NPCE $9.73
- TNXP $26.54
- Analyst Decision
- NPCE Strong Buy
- TNXP Buy
- Analyst Count
- NPCE 6
- TNXP 1
- Target Price
- NPCE $16.67
- TNXP $70.00
- AVG Volume (30 Days)
- NPCE 214.9K
- TNXP 1.9M
- Earning Date
- NPCE 08-12-2025
- TNXP 08-11-2025
- Dividend Yield
- NPCE N/A
- TNXP N/A
- EPS Growth
- NPCE N/A
- TNXP N/A
- EPS
- NPCE N/A
- TNXP N/A
- Revenue
- NPCE $88,570,000.00
- TNXP $9,831,000.00
- Revenue This Year
- NPCE $22.13
- TNXP $21.19
- Revenue Next Year
- NPCE $6.07
- TNXP $722.94
- P/E Ratio
- NPCE N/A
- TNXP N/A
- Revenue Growth
- NPCE 23.32
- TNXP N/A
- 52 Week Low
- NPCE $5.45
- TNXP $6.76
- 52 Week High
- NPCE $18.98
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- NPCE 61.05
- TNXP 32.47
- Support Level
- NPCE $8.88
- TNXP $34.50
- Resistance Level
- NPCE $8.99
- TNXP $29.70
- Average True Range (ATR)
- NPCE 0.39
- TNXP 3.35
- MACD
- NPCE 0.15
- TNXP -1.55
- Stochastic Oscillator
- NPCE 93.98
- TNXP 4.29
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.